Cargando…

FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma

AIMS: To develop a fluorescence in-situ hybridisation (FISH) assay for detecting p16/CDKN2A deletion on paraffin tissue sections for use as an ancillary test to distinguish reactive from malignant mesothelial proliferations. METHOD: Dual-colour FISH for p16/CDKN2A and chromosome 9 (CEP-9) was perfor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chung, Catherine T-S, Santos, Gilda Da Cunha, Hwang, David M, Ludkovski, Olga, Pintilie, Melania, Squire, Jeremy A, Tsao, Ming-Sound
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Group 2010
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989172/ https://www.ncbi.nlm.nih.gov/pubmed/20591913 http://dx.doi.org/10.1136/jcp.2010.076794

Ejemplares similares

Deletions of CDKN2A and MTAP Detected by Copy-Number Variation Array Are Associated with Loss of p16 and MTAP Protein in Pleural Mesothelioma
por: Vrugt, Bart, et al.
Publicado: (2023)

CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure
por: Kettunen, Eeva, et al.
Publicado: (2019)

Genomic Deletion of BAP1 and CDKN2A Are Useful Markers for Quality Control of Malignant Pleural Mesothelioma (MPM) Primary Cultures
por: Sarun, Kadir Harun, et al.
Publicado: (2018)

Transcriptomic Analysis of the Claudin Interactome in Malignant Pleural Mesothelioma: Evaluation of the Effect of Disease Phenotype, Asbestos Exposure, and CDKN2A Deletion Status
por: Rouka, Erasmia, et al.
Publicado: (2017)

Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue
por: Hida, Tomoyuki, et al.
Publicado: (2015)

Frequent homozygous deletion of Cdkn2a/2b in tremolite‐induced malignant mesothelioma in rats
por: Okazaki, Yasumasa, et al.
Publicado: (2020)

Addition of multiple rare SNPs to known common variants improves the association between disease and gene in the Genetic Analysis Workshop 17 data
por: Sykes, Jenna, et al.
Publicado: (2011)

Optimized application of penalized regression methods to diverse genomic data
por: Waldron, Levi, et al.
Publicado: (2011)

Assessment of Hypoxia in the Stroma of Patient-Derived Pancreatic Tumor Xenografts
por: Lohse, Ines, et al.
Publicado: (2014)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice
por: Badhai, Jitendra, et al.
Publicado: (2020)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers
por: Sorino, Claudio, et al.
Publicado: (2023)

Frequent alterations in p16/CDKN2A identified by immunohistochemistry and FISH in chordoma
por: Cottone, Lucia, et al.
Publicado: (2020)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Pleural mesothelioma – case report
por: Klawiter, Anna, et al.
Publicado: (2010)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

Extrathoracic Metastases in Pleural Mesothelioma
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023)

Pleural Mesothelioma in the Era of Immunotherapy
por: Chevallier, Mathieu, et al.
Publicado: (2023)

Prognostic Value of Ki67 Percentage, WT-1 Expression and p16/CDKN2A Deletion in Diffuse Malignant Peritoneal Mesothelioma: A Single-Centre Cohort Study
por: Pezzuto, Federica, et al.
Publicado: (2020)

Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma
por: Woodard, Gavitt A., et al.
Publicado: (2020)

Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma
por: Watanabe, Takuya, et al.
Publicado: (2018)

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition to CDKN2A
por: Tu, Q, et al.
Publicado: (2018)

Optimizing Drug Response Study Design in Patient-Derived Tumor Xenografts
por: Weiss, Jessica, et al.
Publicado: (2022)

The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
por: Chau, Nicole G, et al.
Publicado: (2011)

Thoracoscopy in Pleural Malignant Mesothelioma Diagnosis
por: Tassi, G. F., et al.
Publicado: (1997)

Imaging in staging of malignant pleural mesothelioma
por: Truong, Mylene T, et al.
Publicado: (2004)

Pleural mesothelioma in a couple of brothers
por: Bianchi, Claudio, et al.
Publicado: (2013)

Hedgehog Signaling in Malignant Pleural Mesothelioma
por: Felley-Bosco, Emanuela, et al.
Publicado: (2015)

Life Expectancy in Pleural and Peritoneal Mesothelioma
por: Shavelle, Robert, et al.
Publicado: (2017)

Targeting YAP in malignant pleural mesothelioma
por: Zhang, Wen‐Qian, et al.
Publicado: (2017)

Multimodality treatment of malignant pleural mesothelioma
por: Berzenji, Lawek, et al.
Publicado: (2018)

Modern management of malignant pleural mesothelioma
por: Patel, Shivani C, et al.
Publicado: (2016)

Pleural tuberculosis mimicking malignant mesothelioma
por: Dawood, Wajahat, et al.
Publicado: (2019)

Cytomegalovirus infection in malignant pleural mesothelioma
por: Hunter-Schlichting, DeVon, et al.
Publicado: (2021)

Immunotherapeutic Approaches in Malignant Pleural Mesothelioma
por: Terenziani, Rita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jl4l8sobu4sr6i50qfsein819k